|apersy|

Value | Commercial | Access

poster presentation

A Framework for Market Access Preparedness for microbiome-targeting therapies

We presented our take on commercial strategy and access preparedness for microbiome therapies at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe (Rotterdam, 23-24 May 2023).

Apersy presented a poster on stage, highlighting key commercial success factors and the importance of including reimbursement and payer considerations early in strategic development decisions.

Take the investors word for it…

The panel discussion: Investment in the Microbiome on conference day 1 , May 23, with Denise Kelly (Seventure Partners) and Laurenz Govaerts (EQT Life Sciences) did not pass by the poster content: Even when go-to-market seems far away or commercialisation is not part of the business model, market access potential is part of investor and partner considerations.

Ultimately, pricing and reimbursement will play a big role to get pharma collaborations back on board and fuel investor and partner excitement.

The poster got you interested?

We specialise in new health technologies, disruptive medicines and complex care

Our insights and news

From investor decks to commercial strategy and Market Access Landscapes – we introduce the commercial point of view into product development

Our services

Other recent posts: